Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease.

Institute of Neurology, University College London, Queen Square, London, UK.
Journal of neurology, neurosurgery, and psychiatry (Impact Factor: 4.87). 09/2008; 79(8):955-8. DOI: 10.1136/jnnp.2007.138685
Source: PubMed

ABSTRACT Cognitive impairment is common in multiple sclerosis (MS) and adds significantly to the burden of the disease. The ability to predict future cognitive impairment from imaging obtained at disease onset has not been investigated.
62 patients imaged within 3 months of a clinically isolated syndrome were assessed neuropsychologically 7 years later. Baseline and periodic MRI measures of lesions, atrophy and normal-appearing white and grey matter were regressed against neuropsychological scores to explore the best predictors of cognitive outcome.
28 patients had developed clinically definite MS at follow-up and a further nine met revised McDonald criteria for MS. Deficits in speed of information processing and executive function were the most common abnormalities. Poor performance correlated with high anxiety ratings. Baseline T(1) lesion metrics predicted executive deficits, and new T(2) lesions at the 3-month follow-up predicted slowed information processing. An increase in myo-inositol concentration in normal-appearing white matter over the first 3 years was associated with poor executive function.
MRI variables obtained at the onset of a clinically isolated syndrome can predict future development of cognitive abnormalities. Our findings may have implications in monitoring and treating patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The range of symptoms which occur in multiple sclerosis (MS) can have disabling functional consequences for patients and lead to significant reductions in their quality of life. MS symptoms can also interact with each other, making their management challenging. Clinical trials aimed at identifying symptomatic therapies have generally been poorly designed and have tended to be underpowered. Therefore, the evidence base for the management of MS symptoms with pharmacologic therapies is not strong and tends to rely upon open-label studies, case reports, and clinical trials with small numbers of patients and poorly validated clinical outcome measures. Recently, there has been a growing interest in the management of MS symptoms with pharmacologic treatments, and better-designed, randomized, double-blind, controlled trials have been reported. This chapter will describe the evidence base predominantly behind the various pharmacologic approaches to the management of MS symptoms, which in most, if not all, cases, requires multidisciplinary input. Drugs routinely recommended for individual symptoms and new therapies, which are currently in the development pipeline, will be reviewed. More interventional therapies related to symptoms that are refractory to pharmacotherapy will also be discussed, where relevant.
    Handbook of Clinical Neurology 01/2014; 122:513-62.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive impairment (CI) may occur in clinically isolated syndrome (CIS) patients. While the relationship between CI and magnetic resonance imaging (MRI) has been investigated extensively in multiple sclerosis (MS), MRI correlates of CI in CIS patients are unknown. To investigate the evolution of CI and to determine brain MRI structural correlates associated with CI in CIS patients. This prospective 24-month observational study examined 81 CIS patients treated with 30 µg of intramuscular interferon beta 1a once a week. MRI acquisition and neuropsychological (NP) assessment were performed at baseline, 6, 12 and 24 months. Participants were tested with Czech-validated version of Minimal Assessment of Cognitive Function in MS battery and MRI measures of lesion activity and burden, and global, tissue-specific and regional brain atrophy were performed. Over 24 months, 36 CIS patients developed clinically definite MS (CDMS). CI was observed in 10 (12.3 %) CIS patients at baseline and at the 24 months follow-up. Eight CIS patients changed their CI status over the follow-up (four improved and four worsened). No significant difference in development of CI was detected between stable CIS patients and those who developed CDMS. In multivariate regression and mixed-effect model analyses, no significant relationship was found between NP and MRI parameters. The lack of significant relationship between MRI metrics and cognition in this group of CIS patients could be attributed to several factors including the cognitive reserve, effect of disease-modifying therapy and relatively short follow-up period.
    Journal of Neurology 06/2014; · 3.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Der zunehmende Einsatz der Magnetresonanztomographie (MRT) in der Neurologie hat auch einen Zuwachs an inzidentellen Befunden mit sich gebracht. Eine adäquate Einschätzung von bislang asymptomatischen Patienten, bei denen für eine Multiple Sklerose (MS) typische zerebrale Läsionen im Sinne eines Zufallsbefundes nachgewiesen wurden, war bislang aufgrund der fehlenden Studienlage nicht hinreichend möglich. Erfüllen die MRT-Befunde auch noch die Kriterien für eine räumliche Dissemination nach Barkhof-Tintoré und können Differenzialdiagnosen der MS nicht bestätigt werden, spricht man von einem sog. radiologisch-isolierten Syndrom.In dieser Übersichtsarbeit werden die aktuellen Arbeiten zum radiologisch-isolierten Syndrom erörtert sowie Diagnosekriterien und therapeutische Überlegungen vorgestellt. In zwei Studien konnte gezeigt werden, dass ein Teil der Patienten mit einem radiologisch-isolierten Syndrom ein erhöhtes Risiko aufweist, zeitnah sowohl eine radiologische Progression als auch ein klinisches Erstereignis zu erleiden. Das radiologisch-isolierte Syndrom ist daher als mögliches Vorstadium zum Erstereignis einer MS einzustufen und zieht tiefer gehende therapeutische Überlegungen nach sich. Angesichts der unbefriedigenden Datenlage wird auf den Neurologen neben differenzialdiagnostischen Überlegungen eine umfassende Beraterrolle zukommen. In dieser Arbeit fassen wir das Wissen über das radiologisch-isolierte Syndrom zusammen und schlagen ein pragmatisches Vorgehen für die weitere Diagnostik und Therapie vor.
    Der Nervenarzt 01/2010; 81(10). · 0.86 Impact Factor